PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Ngenla Subcutaneous Injection Special Investigation

Active, not recruiting

Conditions: Growth Hormone Deficiency Without Epiphyseal Closure

Interventions: Drug: NGENLA (Somatrogon)

First Posted Date: 2022-11-02

Last Posted Date: 2025-05-31

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT05602766

Locations: 🇯🇵
Pfizer, Tokyo, Japan

Post Marketing Surveillance(PMS) Study of Lorviqua in Korea

Recruiting

Conditions: Metastatic ALK+ Non Small Cell Lung Cancer

Interventions: Drug: Lorviqua

First Posted Date: 2022-10-31

Last Posted Date: 2025-03-12

Lead Sponsor: Pfizer

Target Recruit Count: 600

Registration Number: NCT05599412

Locations: 🇰🇷
Pfizer, Seoul, Korea, Republic of

A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment

Completed

Conditions: Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

Interventions: Drug: Inotuzumab Ozogamicin

First Posted Date: 2022-10-27

Last Posted Date: 2025-02-04

Lead Sponsor: Pfizer

Target Recruit Count: 32

Registration Number: NCT05597085

Locations: 🇮🇳
Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, Delhi, India
🇮🇳
Fortis Memorial Research Institute, Gurugram, Haryana, India
🇮🇳
Tata Medical Center, Kolkata, WEST Bengal, India

and more 2 locations

A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

Completed

Conditions: Breast Cancer
Breast Carcinoma
Breast Neoplasms
Breast Tumors
Cancer of Breast

Interventions: Drug: Palbociclib plus hormonal treatment - first line treatment
Drug: Palbociclib plus hormonal treatment - second line treatment

First Posted Date: 2022-10-18

Last Posted Date: 2023-12-19

Lead Sponsor: Pfizer

Target Recruit Count: 150

Registration Number: NCT05584644

Locations: 🇮🇳
HCG Cancer Centre, Ahmedabad, Gujarat, India, India
🇮🇳
Bhagwan Mahaveer Cancer Hospital and Research Centre, Bajaj Nagar, Jaipur, Rajasthan, India, India
🇮🇳
Hemato Oncology Clinic Ahmedabad Private Limited, Rajpath Club Lane ,Gujarat, India, Ahmedabad, India

and more 2 locations

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

Phase 3

Active, not recruiting

Conditions: Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo

Interventions: Drug: Placebo
Drug: Ritlecitinib

First Posted Date: 2022-10-17

Last Posted Date: 2025-02-27

Lead Sponsor: Pfizer

Target Recruit Count: 581

Registration Number: NCT05583526

Locations: 🇨🇳
The First Hospital of China Medical University/Dermatology and STD Department, Shenyang, Liaoning, China
🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China
🇪🇸
Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Canarias, Spain

and more 107 locations

Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity

Phase 2

Terminated

Conditions: Diabetes Mellitus
Obesity

Interventions: Other: Placebo
Drug: PF-07081532
Drug: Rybelsus

First Posted Date: 2022-10-14

Last Posted Date: 2024-08-01

Lead Sponsor: Pfizer

Target Recruit Count: 902

Registration Number: NCT05579977

Locations: 🇨🇦
LMC Clinical Research Inc. (Bayview), Toronto, Ontario, Canada
🇺🇸
San Fernando Valley Health Institute, Canoga Park, California, United States
🇺🇸
Catalina Research Institute, LLC, Montclair, California, United States

and more 83 locations

A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: PF-07817883
Drug: Midazolam
Drug: Moxifloxacin

First Posted Date: 2022-10-14

Last Posted Date: 2024-11-21

Lead Sponsor: Pfizer

Target Recruit Count: 94

Registration Number: NCT05580003

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.

Completed

Conditions: Rheumatoid Arthritis

Interventions: Other: patterns of use of combination therapy and monotherapy

First Posted Date: 2022-10-12

Last Posted Date: 2023-04-13

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT05576051

Locations: 🇺🇸
Pfizer, New York, New York, United States

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

Phase 1

Recruiting

Conditions: Breast Cancer

Interventions: Drug: ARV-471
Drug: Ribociclib

First Posted Date: 2022-10-10

Last Posted Date: 2025-02-11

Lead Sponsor: Pfizer

Target Recruit Count: 47

Registration Number: NCT05573555

Locations: 🇺🇸
Moffitt McKinley Hospital, Tampa, Florida, United States
🇺🇸
Stanford Women's Cancer Center, Palo Alto, California, United States
🇺🇸
UCSF Medical Center at Mission Bay, San Francisco, California, United States

and more 41 locations

Study to Evaluate Safety and Effects of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs in People Treated for Rheumatoid Arthritis

Completed

Conditions: Arthritis, Rheumatoid

First Posted Date: 2022-10-07

Last Posted Date: 2023-06-28

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT05572567

Locations: 🇯🇵
Pfizer, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy